Citigroup
AXSM icon

Citigroup’s Axsome Therapeutics AXSM Stock Holding History

Citigroup’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$2.25M – 5832
2024
Q3 		$2.25M Buy
+25,000
New +$2.18M ﹤0.01% 2571
2023
Q4 		– Sell
-27,400
Closed -$1.91M – 5697
2023
Q3 		$1.91M Buy
+27,400
New +$2.05M ﹤0.01% 2012
2022
Q3 		– Sell
-26,700
Closed -$1.02M – 5824
2022
Q2 		$1.02M Buy
+26,700
New +$844K ﹤0.01% 2626
2021
Q1 		– Sell
-8,400
Closed -$684K – 6257
2020
Q4 		$684K Sell
8,400
-25,800
-75% -$1.93M ﹤0.01% 3925
2020
Q3 		$2.44M Buy
34,200
+1,000
+3% +$77.9K ﹤0.01% 2475
2020
Q2 		$2.73M Buy
+33,200
New +$2.56M ﹤0.01% 2443

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's AXSM Position: Q2 2026 in Review

Citigroup reduced its Axsome Therapeutics (AXSM) stake by 26% in Q2 2026, selling an estimated $10.6M and leaving 136,858 shares worth $33.5M. The position accounts for 0.01% of the portfolio, ranked #908.

Citigroup first reported a position in AXSM in Q2 2016 and has held it in 35 quarters since. The position peaked at $37.3M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Citigroup held 136,858 shares of Axsome Therapeutics worth $33.5M as of Q2 2026.
  • Citigroup sold 48,800 Axsome Therapeutics shares in Q2 2026, an estimated $10.6M.
  • Axsome Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #908 holding.
  • Citigroup first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 35 quarters since.
  • Citigroup's Axsome Therapeutics position peaked at $37.3M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.